PITTSBURGH, PA – March 8, 2021 – Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has appointed Christopher J. P. Velis to the company’s Board of Directors.
Mr. Velis is an entrepreneur and venture capitalist who has pioneered some of the most innovative medical technologies brought to market in the last decades. As Founder and Executive Chairman of Miraki Innovation, he forecasts imminent global health and medical challenges, uncovers technologies at leading research institutions and assembles teams of industry experts to solve these global problems. Mr. Velis not only offers investment guidance and critical research and industry connections, but also helps guide each portfolio company along the fund’s proven, repeatable process that reduces new venture risk and enhances returns.
Auris Health, recognized by CNBC as one of the 50 most disruptive companies in the world, is one of a number of ventures founded, grown or brought to exit by Mr. Velis. Companies Mr. Velis has worked on have set the industry gold standard for motion preservation, regeneration of cartilage and soft tissue through the use of novel peptides, tissue regeneration using DNA pairs, and stem cell and PRP technologies for use in regenerative medicine. Throughout his 27-year career, Mr. Velis has also represented more than 150 medical device companies in a variety of business transactions including licensing agreements, joint ventures and M&A.
Mr. Velis has spoken at the Hamlyn Symposium on Medical Robotics, China’s Global Innovation and Entrepreneurship Fair, the U.A.E.’s Innovation Week, Massachusetts General Hospital’s Biotech Funding Panel and Harvard University’s Medical and Kennedy Schools. In 2016, Mr. Velis was honored by the U.A.E.’s Ministry of Health for his commitment to bringing medtech innovation to Middle East and North Africa. He graduated from the University of Massachusetts Amherst with a Bachelor of Arts in Economics and earned a Master of Business from the Questrom School of Business at Boston University.
“We are delighted to welcome Chris to our Board of Directors. His vast entrepreneurial and venture capitalist experience in innovative medical technologies will provide significant value to Noveome,” said William Golden, Founder, Chairman and CEO of Noveome.
Mr. Velis added, “I’m excited to join the Noveome board and look forward to helping the company move toward commercialization of its novel biologic ST266.”
About Noveome Biotherapeutics, Inc.
Based in Pittsburgh, Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome has completed a Phase 2 open-label clinical trial that demonstrated the benefit ST266 had in healing persistent corneal epithelial defects (PEDs). ST266 is also being evaluated in a Phase 1 open-label clinical trial to establish the safety of ST266 in intranasal transcribriform delivery from nose-to-brain and eye. The company is currently planning a follow-up clinical study to further characterize the efficacy and safety of ST266 for the treatment of PEDs and is about to begin a Phase 1 study evaluating the safety of intravenously administered ST266 in COVID-19 patients. For more information, visit www.noveome.com.
CG Life for Noveome Biotherapeutics, Inc.